4 results about "Late onset" patented technology

The present disclosure provides methods of treating, preventing, or delaying the onset of a late-onset neurodegenerative disease, e.g., Niemann-Pick type C, or a symptom thereof in a subject in need thereof, comprising administering a therapeutically effective amount of acetyl-leucine to the subject, wherein the subject is heterozygous NPC1 gene mutation carrier.

The invention relates to application of ginsenoside Rg4 as a unique active ingredient in preparation of a medicine for improving male delayed gonad hypofunction, belonging to the field of biological medicine. According to the invention, the action mechanism of the Rg4 for improving LOH is defined for the first time: the Rg4 can specifically up-regulate the mRNA expression quantity of StAR and StARD7 in a testis tissue, and promote the transport of cholesterol to the inner mitochondrial membrane of a testis Leydig cell from the transcriptional level; the Rg4 improves the mRNA expression quantity of P450scc, 3 beta-HSD in testicular tissues by promoting the efficient transport of cholesterol, enhances the conversion of cholesterol to pregnenolone and the catalytic synthesis of subsequent steroids, and improves the endogenous testosterone synthesis capability; the Rg4 can recover the negative feedback regulation function of an HPG axis, regulate secretion of pituitary LH and FSH to physiological steady state, and avoid abnormal fluctuation of hormone level. The invention fills the technical blank of Rg4 in the field of LOH gene regulation and control.

To provide technologies for diagnosing the risk of developing delayed ataxia in dogs.SOLUTION: Provided is a method for diagnosing the risk of developing delayed ataxia comprising detecting the presence of a haplotype lacking the Proteolipid protein 1 (PLP1) gene on the genome of a subject dog, the detection of the haplotype indicating that the subject dog has the risk of developing delayed ataxia or the subject dog gives birth to offspring having the risk of developing delayed ataxia.SELECTED DRAWING: None

The invention discloses a traditional Chinese medicine composition with a yang warming effect for treating irinotecan delayed diarrhea, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises the following components in parts by weight: 6-12 parts of ginseng, 3-9 parts of dried ginger, 9-15 parts of bighead atractylodes rhizome, 3-6 parts of honey-fried licorice root, 6-12 parts of fructus psoraleae, 3-9 parts of myristica fragrans, 1-3 parts of fructus evodiae, 3-6 parts of schisandra chinensis, 9-15 parts of poria cocos, 12-18 parts of Chinese yam, 6-12 parts of lotus seed and 6-12 parts of white hyacinth bean. The traditional Chinese medicine composition with the yang warming effect for treating irinotecan delayed diarrhea focuses on the pathogenesis of spleen-kidney yang deficiency and water-dampness downward flow, can cover 1-4 levels of diarrhea, is free of western medicine side effects, can improve accompanying symptoms such as intolerance of cold and abdominal distension, meets the requirements of different patients, and improves chemotherapy compliance.